By IDSE News Staff
Pivotal studies of some biomedical HIV and sexually transmitted infection (STI) prevention interventions have excluded cisgender women or demonstrated low efficacy among them, limiting their prevention options relative to other populations who experience a high incidence of HIV and STIs.
Perhaps the problem lies in the way these studies are designed, according to Jeanne Marrazzo, MD, MPH, the director of the National Institute of Allergy and Infectious Diseases